Gene expression software firm Iobion, spun out of privately held Stratagene two years ago, will be folded back into the larger firm upon its merger with publicly traded Hycor, Stratagene said last week

Stratagene’s merger with diagnostic manufacturer Hycor is expected to close in the fourth quarter of 2003. The combined entity, to be named Stratagene, will trade on Nasdaq, generate combined revenues of over $85 million for 2003, and employ around 500 people. Hycor and Iobion will be wholly owned subsidiaries of Stratagene.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.